TrialBritish journal of cancer2017

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.

Dimitrios Mavroudis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.